On November 6, EVEREST MED fell 5.32% in regular trading, trading at HK$26.5, with turnover of HK$37.18 million.
Recent market attention had been driven by the company’s mRNA technology platform update, but the latest publicly available coverage indicated that the earlier catalyst was already reflected over prior sessions, with short-term funds showing profit-taking pressure.
Background context shows the company recently held an mRNA R&D day and disclosed first human data for EVM16, progress of EVM14, and continued work on its AI-enabled neoantigen prediction and mRNA/LNP platform spanning personalized cancer vaccines, off-the-shelf tumor vaccines, immunomodulatory vaccines, and in vivo CAR-T. Separately, the company’s October share movement filing showed 172,150 new ordinary shares issued from post-IPO option exercises, implying only a modest increase in share capital.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments